Last reviewed · How we verify
carboxymethylcellulose based eye drop formula
carboxymethylcellulose based eye drop formula is a ocular lubricant Small molecule drug developed by Allergan. It is currently in Phase 3 development for Dry eye syndrome.
Carboxymethylcellulose based eye drops act as artificial tears to lubricate and moisten the eye, providing relief from dryness and irritation.
Carboxymethylcellulose based eye drops act as artificial tears to lubricate and moisten the eye, providing relief from dryness and irritation. Used for Dry eye syndrome.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | carboxymethylcellulose based eye drop formula |
|---|---|
| Sponsor | Allergan |
| Drug class | ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Carboxymethylcellulose is a synthetic polymer that mimics the properties of natural tears. It coats the surface of the eye, reducing friction and evaporation, thereby alleviating symptoms associated with dry eye syndrome.
Approved indications
- Dry eye syndrome
Common side effects
- Eye irritation
- Blurred vision
Key clinical trials
- A Study to Compare a New Eye Drop Formulation With Refresh Contacts® (PHASE3)
- A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- carboxymethylcellulose based eye drop formula CI brief — competitive landscape report
- carboxymethylcellulose based eye drop formula updates RSS · CI watch RSS
- Allergan portfolio CI
Frequently asked questions about carboxymethylcellulose based eye drop formula
What is carboxymethylcellulose based eye drop formula?
How does carboxymethylcellulose based eye drop formula work?
What is carboxymethylcellulose based eye drop formula used for?
Who makes carboxymethylcellulose based eye drop formula?
What drug class is carboxymethylcellulose based eye drop formula in?
What development phase is carboxymethylcellulose based eye drop formula in?
What are the side effects of carboxymethylcellulose based eye drop formula?
Related
- Drug class: All ocular lubricant drugs
- Manufacturer: Allergan — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Dry eye syndrome
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing